Phase 2 Solid Tumor Immunotherapy Trial Using HLA-Haploidentical Transplant and Donor NK Cells: The STIR Trial

Protocol No
IIT-THAKAR-STIR
Principal Investigator
David Margolis
Phase
II
Summary
The purpose of this study is to evaluate the safety and efficacy of performing an allogeneic transplant followed by NK cell infusion in patients with solid tumors. This study is also asking whether the addition of extra immune cells from the same haploidentical donor one week after transplant is safe and can help treat your cancer. These cells are known as natural killer cells or NK cells. The addition of NK cells is considered part of the investigational therapy. The experimental part of this treatment protocol is receiving the allogeneic HPCT and donor NK cells.
Description
The purpose of this study is to evaluate the safety and efficacy of performing an allogeneic
transplant followed by NK cell infusion in patients with solid tumors. This study is also asking whether the addition of extra immune cells from the same haploidentical
donor one week after transplant is safe and can help treat your cancer. These cells are known as
natural killer cells or NK cells. The addition of NK cells is considered part of the investigational
therapy.
The experimental part of this treatment protocol is receiving the allogeneic HPCT and donor
NK cells.
Participating Institutions
Froedtert Hospital
Childrens Hospital of Wisconsin
Status
OPEN TO ACCRUAL
Share This: